Feverfew
Feverfew is a long-popular migraine preventive whose best trial produced a difference of only 0.6 attacks per month versus placebo, and whose older positive studies were tiny. Cochrane rates the evidence low quality — the honest summary is that feverfew probably does very little.
What the science says
- Migraine frequency Limited evidence
The 2015 Cochrane review covered six trials (561 patients) and could not pool them. The largest rigorous trial (n = 218, MIG-99 CO2 extract) reduced attacks from 4.8 to 2.9 per month versus 4.8 to 3.5 on placebo — a between-group difference of 0.6 attacks per month, rated low quality evidence.
- Earlier positive trials do not hold up Limited evidence
Three trials reporting clear benefit had only 17 to 60 participants each, while two more rigorous trials (n = 50 and n = 147) found no significant difference from placebo. This is the classic pattern of an effect that shrinks as study quality rises.
- Attack severity, duration and nausea Limited evidence
Across the included trials no statistically significant differences were found for migraine intensity or duration, incidence or severity of nausea and vomiting, or global assessment. Any benefit appears confined to attack count.
Dosage & safety
Scientific references
Where to buy
Nature's Answer, Feverfew Extract, Alcohol-Free, 1 fl oz (30 ml)
View on iHerbReferral link — this site may earn a commission on purchases.
Related in Brain & cognition
- Vitamin B2 (Riboflavin) Moderate evidence
- Choline Moderate evidence
- Magnesium L-Threonate Limited evidence
- Phosphatidylserine Limited evidence
- Lecithin (Phosphatidylcholine) Limited evidence
- Agmatine Sulfate Limited evidence